{"denoms":[{"counts":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"70"},{"groupId":"BG003","value":"164"}],"units":"Participants"}],"groups":[{"description":"Participants previously treated with bortezomib received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"BG000","title":"Part 1: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"BG001","title":"Part 2: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 of Cycle 1. If all doses were well-tolerated the dose was escalated to 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 of subsequent cycles, for up to 12 cycles.","id":"BG002","title":"Part 2: Carfilzomib 20/27 mg/m²"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"81"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"83"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"70"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"94"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"67"}]}],"title":"0 (Fully Active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"87"}]}],"title":"1 (Restrictive but ambulatory)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"9"}]}],"title":"2 (Ambulatory but unable to work)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Missing"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active; 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, no self-care, confined to bed or chair; 5 = Death.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"20"}]}],"title":"SPEP and UPEP"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"108"}]}],"title":"SPEP"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"22"}]}],"title":"UPEP"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"11"}]}],"title":"SFLC Only"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"IgA, by Immunoglobulin Assay Only"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Missing"}],"description":"Measurable disease categories defined as:\n\nSPEP: Serum M-protein ≥ 1 g/dL by serum protein electrophoresis (SPEP);\n\nUPEP: Urine M-protein ≥ 200 mg/24 hour by urine protein electrophoresis (UPEP);\n\nSPEP and UPEP: M-protein levels ≥ 1 g/dL in serum and ≥ 200 mg/24 hours;\n\nSFLC Only: Detectable using serum free light chain (SFLC) assay only (participants enrolled prior to Amendment 2);\n\nIgA only: For patients with immunoglobulin A (IgA) myeloma for whom SPEP is considered unreliable, quantitative immunoglobulin (e.g. nephelometry or turbidometry) was performed.","paramType":"NUMBER","title":"Measurable Disease Category","unitOfMeasure":"participants"}],"populationDescription":"Safety Population: All patients enrolled on study and who received at least 1 dose of carfilzomib."}